Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel
NASDAQ:VALN

Valneva Q3 2026 Earnings Date & Estimates

Valneva logo
$5.92 +0.05 (+0.85%)
As of 09:59 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Valneva is estimated to report Q3 2026 earnings on Tuesday, November 24, 2026, before market opens. The conference call is scheduled for 9:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
9:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Valneva in Q3 2026

Valneva is expected to post earnings of -$0.23 per share on revenue of $43.67 million. In the same quarter a year earlier Valneva reported -$0.61 per share on revenue of $34.01 million. Valneva last reported on August 14, 2026, posting -$0.40 per share and missing the -$0.1886 consensus estimate. Valneva has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.23
Expected Revenue
$43.67 million
Prior-Year EPS
-$0.61
Prior-Year Revenue
$34.01 million
Expected Revenue Growth
+28.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.40 (Missed by -$0.2114)
Last Quarter Revenue
$39.37 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Valneva Q3 2026 Earnings FAQ

Valneva (NASDAQ:VALN) is estimated to report Q3 2026 earnings on Tuesday, November 24, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Valneva's Q3 2026 earnings conference call is scheduled for Tuesday, November 24, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Valneva to post earnings of -$0.23 per share for Q3 2026.

The consensus revenue estimate for Valneva is $43.67 million for Q3 2026.

Valneva Earnings Headlines

Valneva's four-strain Shigella vaccine clears phase 2 in adults and infants as antibiotics fail
November 10 at 12:32 AM  |  msn.comhttps://www.msn.com/en-us/health/general/valneva-s-four-strain-shigella-vaccine-clears-phase-2-in-adults-and-infants-as-antibiotics-fail/ar-AA2haDzU
Valneva Reports Five-Year Antibody Persistence for Chikungunya Vaccine
November 10 at 1:44 PM  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/11/63113122/valneva-reports-five-year-antibody-persistence-for-chikungunya-vaccine?utm_source=snapi
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
November 12 at 1:00 AM  |  American Alternative (Ad)
Valneva SE Announces Positive Phase 2 Results For Tetravalent Shigella Vaccine Candidate S4V2
November 10 at 9:29 AM  |  marketscreener.comM
Valneva Reports Five-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ
November 10 at 9:29 AM  |  rttnews.comhttps://www.rttnews.com/3712241/valneva-reports-five-year-antibody-persistence-for-chikungunya-vaccine-ixchiq.aspx
Valneva's Chikungunya Vaccine Shows Durable Antibody Persistence in All Age Groups
November 10 at 9:29 AM  |  marketscreener.comM
See More Valneva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Valneva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Valneva and other key companies, straight to your email.

About Valneva

Valneva (NASDAQ:VALN) is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners.

Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.

The company continues to develop vaccines for diseases with limited prevention options. Its pipeline has included VLA15, a Lyme disease vaccine candidate being developed with Pfizer, alongside other research and development programs.

View Valneva Profile
Earnings Tools